Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ViiV Healthcare
- 30 Oct 2017 Status changed from active, no longer recruiting to recruiting.
- 26 Oct 2017 New trial record
- 19 Oct 2017 Status has been changed from recruiting to Active no longer recruiting.